Cargando…

Anti SARS-CoV 2 IgG antibody response in fully vaccinated Covishield (AZD1222) and Covaxin (BBV-152) recipients: a study done in southern part of West Bengal, India

BACKGROUND AND OBJECTIVES: Vaccination being the only way to reduce mortality from the dreaded COVID-19 disease, the vaccine was introduced in India as per the advice of the National Expert Group on January 16, 2021. Duration of immune response elicited by the vaccines has always been a matter of co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Satpathi, Partha Sarathi, Endow, Sayantani, Gantait, Kripasindhu, Chand, Pearl Helena, Jaiswal, Abhishek, Jana, Biswajit, Kundu, Panchanan, Ghosh, Tarapada
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Tehran University of Medical Sciences 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9723424/ https://www.ncbi.nlm.nih.gov/pubmed/36531814 http://dx.doi.org/10.18502/ijm.v14i5.10953

Ejemplares similares

Azd-1222/bbv-152: Diabetic ketoacidosis: 2 case reports
Publicado: (2022)

Effectiveness of BBV152/Covaxin and AZD1222/Covishield vaccines against severe COVID-19 and B.1.617.2/Delta variant in India, 2021: a multi-centric hospital-based case-control study
por: Bhatnagar, Tarun, et al.
Publicado: (2022)

Inactivated vaccine Covaxin/BBV152: A systematic review
por: Ahmed, Tousief Irshad, et al.
Publicado: (2022)

AZD-1222/BBV-152: Central nervous system demyelination: 29 case reports
Publicado: (2022)

Pityriasis Rosea Following Covaxin (BBV152) Vaccination for COVID-19
por: Singh, Bhabani S. T. P., et al.
Publicado: (2022)

Psoriasis Flare-Up After COVAXIN BBV152 Whole Virion Inactivated Vaccine
por: Infimate, DJ L, et al.
Publicado: (2022)

Prime-Boost Vaccination With Covaxin/BBV152 Induces Heightened Systemic Cytokine and Chemokine Responses
por: Kumar, Nathella Pavan, et al.
Publicado: (2021)

Humoral Immune Response to BBV152 (Covaxin) SARS-CoV-2 Vaccine in Patients on Hemodialysis
por: Vijayaraghavan, Radha, et al.
Publicado: (2023)

Clinical outcomes in individuals hospitalized with SARS-CoV-2 Delta variant (B.1.617.2) who had been vaccinated with Covishield (ChAdOx1) and Covaxin (BBV-152)
por: Munigela, Apoorva, et al.
Publicado: (2022)

AZD1222 (Covishield) vaccination for COVID-19: Experiences, challenges, and solutions in Nepal
por: Sah, Ranjit, et al.
Publicado: (2021)

Persistence of Antibodies Against Spike Glycoprotein of SARS-CoV-2 in Healthcare Workers Post Double Dose of BBV-152 and AZD1222 Vaccines
por: Choudhary, Hari Ram, et al.
Publicado: (2021)

Two Cases of Double-Positive Antineutrophil Cytoplasmic Autoantibody and Antiglomerular Basement Membrane Disease After BBV152/Covaxin Vaccination
por: Prema, Jansi, et al.
Publicado: (2021)

Nephrotic Syndrome with Acute Kidney Injury after Covaxin (BBV152) COVID-19 Vaccination: A Case from India
por: Patel, Prem S., et al.
Publicado: (2023)

Immunogenicity and safety of homologous and heterologous booster vaccination of ChAdOx1 nCoV-19 (COVISHIELD™) and BBV152 (COVAXIN®): a non-inferiority phase 4, participant and observer-blinded, randomised study
por: Rose, Winsley, et al.
Publicado: (2023)

“Covishield and Covaxin” – India's contribution to global COVID-19 pandemic
por: Raina, Sunil Kumar, et al.
Publicado: (2021)

Immunogenic and reactogenic efficacy of Covaxin and Covishield: a comparative review
por: Das, Swarnali, et al.
Publicado: (2022)

Single-dose of BBV-152 and AZD1222 increases antibodies against spike glycoprotein among healthcare workers recovered from SARS-CoV-2 infection
por: Parai, Debaprasad, et al.
Publicado: (2021)

Immune responses to a single dose of the AZD1222/Covishield vaccine in health care workers
por: Jeewandara, Chandima, et al.
Publicado: (2021)

Preclinical evaluation of safety and immunogenicity of a primary series intranasal COVID-19 vaccine candidate (BBV154) and humoral immunogenicity evaluation of a heterologous prime-boost strategy with COVAXIN (BBV152)
por: Sunagar, Raju, et al.
Publicado: (2022)

PERSISTENCE AND DYNAMICITY OF SARS-COV-2 ANTIBODY RESPONSE AFTER DOUBLE DOSE OF BBV-152 AND AZD1222 VACCINES: A PROSPECTIVE, LONGITUDINAL, YEAR-LONG COHORT STUDY
por: Bhattacharya, D., et al.
Publicado: (2023)

Effectiveness of the BBV-152 and AZD1222 vaccines among adult patients hospitalized in tertiary hospitals in Odisha with symptomatic respiratory diseases: A test-negative case–control study
por: Bhattacharya, Debdutta, et al.
Publicado: (2023)

Humoral antibody kinetics with ChAdOx1-nCOV (Covishield™) and BBV-152 (Covaxin™) vaccine among Indian Healthcare workers: A 6-month longitudinal cross-sectional Coronavirus Vaccine-induced antibody titre (COVAT) study
por: Singh, Awadhesh Kumar, et al.
Publicado: (2022)

Kinetics of immune responses to the AZD1222/Covishield vaccine with varying dose intervals in Sri Lankan individuals
por: Jeewandara, Chandima, et al.
Publicado: (2021)

Determinants of associated events following AZD1222 (Covishield) vaccination in a high-risk population in Nepal
por: Poudel, Kapil Madi, et al.
Publicado: (2022)

Kinetics of immune responses to the AZD1222/Covishield vaccine with varying dose intervals in Sri Lankan individuals
por: Jeewandara, Chandima, et al.
Publicado: (2022)

Seroconversion Rate After SARS-CoV-2 Infection and Two Doses of Either ChAdOx1-nCOV COVISHIELD™ or BBV-152 COVAXIN™ Vaccination in Renal Allograft Recipients: An Experience of Two Public and Private Tertiary Care Center
por: Prasad, Narayan, et al.
Publicado: (2022)

Comparison of in-hospital COVID-19 related outcomes between COVISHIELD and COVAXIN recipients
por: Suri, Tejas M., et al.
Publicado: (2022)

Bbv-152: Subacute thyroiditis: case report
Publicado: (2022)

BBV-152: Myocarditis and myositis: case report
Publicado: (2022)

BBV-152: Herpes zoster: case report
Publicado: (2022)

BBV-152: Reactivation of uveitis : case report
Publicado: (2022)

Adverse effects after first and second dose of covishield and covaxin: A longitudinal study
por: Mittal, Amit, et al.
Publicado: (2022)

Antibody response after first and second-dose of ChAdOx1-nCOV (Covishield(TM)®) and BBV-152 (Covaxin(TM)®) among health care workers in India: The final results of cross-sectional coronavirus vaccine-induced antibody titre (COVAT) study
por: Singh, Awadhesh Kumar, et al.
Publicado: (2021)

Dynamicity and persistence of severe acute respiratory syndrome coronavirus-2 antibody response after double dose and the third dose with BBV-152 and AZD1222 vaccines: A prospective, longitudinal cohort study
por: Parai, Debaprasad, et al.
Publicado: (2022)

A machine learning-based approach to determine infection status in recipients of BBV152 (Covaxin) whole-virion inactivated SARS-CoV-2 vaccine for serological surveys
por: Singh, Prateek, et al.
Publicado: (2022)

Prevalence of COVID-19 vaccines (Sputnik V, AZD-1222, and Covaxin) side effects among healthcare workers in Birjand city, Iran
por: Zare, Hamed, et al.
Publicado: (2021)

Factors Associated With the Decay of Anti-SARS-CoV-2 S1 IgG Antibodies Among Recipients of an Adenoviral Vector-Based AZD1222 and a Whole-Virion Inactivated BBV152 Vaccine
por: Selvavinayagam, Sivaprakasam T., et al.
Publicado: (2022)

BBV-152: Cutaneous small vessel vasculitis: case report
Publicado: (2021)

Bbv-152: Cutaneous small-vessel vasculitis: case report
Publicado: (2021)

2371. A study to describe the pattern of cutaneous adverse effects of COVID-19 vaccines (Covishield and Covaxin )
por: Mitra, Debdeep, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_14crae7shlqn0gitkerehsa05q